Our business model is designed to bring solutions to patients while generating shareholder value, by translating our proprietary technology into commercial drug products in a rapid and cost-effective way.

Our latest corporate presentation can be found by clicking here, which Ali Mortazavi, CEO, presented at the Cowen Healthcare Conference on 13 March 2018 - Click here for the webcast. 


Investment case

Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.


“With the significant advancement of our liver delivery system, we will be able to deliver on the promise of RNAi being the next class of therapeutics”
Ali Mortazavi, Chief Executive Officer

Results, reports & presentations

ara 2017 pic.PNG

Full Year Results 2017

Showing: All Size

Full Year Results 2017

298KB Download

Half Year Results 2017

154KB Download

Full Year Results 2016

898KB Download

Half Year Results 2016

614KB Download

Full Year Results 2015

1MB Download

Corporate governance 

Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.


We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.